Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aziz Nazha

Showing results (81-90 of 121) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|January 21, 2020
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantationHassan Awada, Reda Z Mahfouz, Jibran Durrani, et al.
Haematologica|March 20, 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failureAziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, et al.
Leukemia Research|January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Iscience|September 26, 2022
A machine learning model of response to hypomethylating agents in myelodysplastic syndromesNathan Radakovich, David A Sallman, Rena Buckstein, et al.
Leukemia & Lymphoma|April 9, 2020
Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromesGuillermo Garcia-Manero, Naveen Pemmaraju, Yesid Alvarado, et al.
Haematologica|August 16, 2019
Genomics of therapy-related myeloid neoplasmsTeodora Kuzmanovic, Bhumika J Patel, Srinivasa R Sanikommu, et al.
Blood Advances|April 14, 2022
Patient-specific comorbidities as prognostic variables for survival in myelofibrosisAndrew L Sochacki, Cosmin Adrian Bejan, Shilin Zhao, et al.
Communications Biology|September 8, 2020
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasiaYihong Guan, Edward F Greenberg, Metis Hasipek, et al.
Leukemia|May 26, 2018
Consequences of mutant TET2 on clonality and subclonal hierarchyCassandra M Hirsch, Aziz Nazha, Kassy Kneen, et al.
Pageof 13

Showing results (81-90 of 121) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|January 21, 2020
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantationHassan Awada, Reda Z Mahfouz, Jibran Durrani, et al.
Haematologica|March 20, 2016
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failureAziz Nazha, Rami S Komrokji, Guillermo Garcia-Manero, et al.
Leukemia Research|January 19, 2016
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agentsAziz Nazha, Mikkael A Sekeres, Guillermo Garcia-Manero, et al.
Blood|April 25, 2013
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutationFarhad Ravandi, Mona Lisa Alattar, Michael R Grunwald, et al.
Iscience|September 26, 2022
A machine learning model of response to hypomethylating agents in myelodysplastic syndromesNathan Radakovich, David A Sallman, Rena Buckstein, et al.
Leukemia & Lymphoma|April 9, 2020
Results of a Phase 1/2a dose-escalation study of FF-10501-01, an IMPDH inhibitor, in patients with acute myeloid leukemia or myelodysplastic syndromesGuillermo Garcia-Manero, Naveen Pemmaraju, Yesid Alvarado, et al.
Haematologica|August 16, 2019
Genomics of therapy-related myeloid neoplasmsTeodora Kuzmanovic, Bhumika J Patel, Srinivasa R Sanikommu, et al.
Blood Advances|April 14, 2022
Patient-specific comorbidities as prognostic variables for survival in myelofibrosisAndrew L Sochacki, Cosmin Adrian Bejan, Shilin Zhao, et al.
Communications Biology|September 8, 2020
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasiaYihong Guan, Edward F Greenberg, Metis Hasipek, et al.
Leukemia|May 26, 2018
Consequences of mutant TET2 on clonality and subclonal hierarchyCassandra M Hirsch, Aziz Nazha, Kassy Kneen, et al.
Pageof 13